By Charles Castano – Clinical trial logistics is undergoing a profound digital transformation, moving from traditional manual processes toward integrated, technology-driven management systems that enhance efficiency, data integrity, and speed.
Read More
Clinical rotations sit at the center of health professional education, translating theory into real patient care; yet, the process of securing placements and preceptors has historically been fragmented, slow and uneven across regions and specialties.
By Jen Lamppa PhD – Clinical trials have a diversity problem. Despite years of effort, the participants in many studies still fail to reflect the true demographics of the populations they aim to serve. The consequences are profound: limited applicability of results, missed insights, and health inequities that persist across generations.
By Hilary Marston MD MPH & Kevin Bugin PhD – Breakthroughs in science and technology are advancing innovation in more areas of medicine, providing novel treatment options for patients. The scientific community has a deepening understanding of disease and human biology, and of the enormous potential afforded through new technologies.
By Wendy Morahan – Despite the critical nature of clinical trials in pharmaceutical research and development, trial stakeholders often struggle with managing scattered data across locations, systems and applications.
By Harsha K Rajasimha – AI is heralding a new era in drug development, promising groundbreaking solutions to longstanding challenges. Traditional clinical trials are often plagued by manual processes, leading to prolonged timelines and soaring costs.
By Hiren Thakkar – Inadequate ethnic diversity in clinical trials, tight eligibility criteria, delayed or missing prescription recommendations for certain communities, and access gaps affecting global health are all hot topics in academia, business, and government.
By Emily Newton – Like many other industries, the medical sector is ramping up its AI adoption. This technology has shown significant potential in many use cases, particularly clinical trials, but some concerns remain. As more organizations use AI in medical research, more ethical questions emerge.
By Gunnar Esiason – I have cystic fibrosis (CF), a rare genetic condition that was historically known as a childhood disease. Today, CF is anything but that, and it’s due in large part to my community’s willingness to rally around clinical trial programs.